Novo Nordisk (NOVO) Q4 2025 London conference call earnings summary

Executive summary

• Sales and profit more than doubled over five years, with 2025 sales up 10% at CER to DKK 309.1 billion and operating profit up 6% at CER, driven by GLP-1 and obesity care, especially WegovyⓇ.

• Obesity care sales surged 31% at CER to DKK 82.3 billion, with international operations up 73% and the Wegovy pill launch marking a record in new prescriptions.

• Rare disease sales increased 9% at CER, while diabetes care was flat in DKK but up 4% at CER, led by GLP-1 products.

• Major R&D milestones included phase 3 completion for CagriSema, phase 2 for zenagamtide, and multiple regulatory submissions.

• Executive management changes and a 10% workforce reduction were announced, effective February 2026.

Financial highlights

• Net profit for 2025 reached DKK 102.4 billion, with diluted EPS up 2% to DKK 23.03 and free cash flow of DKK 28.3–29 billion.

• Gross margin declined to 81.0% from 84.7% due to restructuring and acquisition costs; operating margin was 41.3%.

• DKK 52–53 billion was paid in dividends, with a 30th consecutive year of increases and a payout ratio around 50%.

• CAPEX spending was DKK 60 billion, mainly for manufacturing, and DKK 30 billion on business development/M&A, including the Akero acquisition.

• Share buyback program of DKK 15 billion was initiated for 2026.

Outlook and guidance

• 2026 guidance: adjusted sales and operating profit growth expected at -5% to -13% CER, reflecting price declines, LOE, and US rebate provision reversal.

• Non-adjusted 2026 guidance: sales growth -1% and operating profit growth 11% at CER, boosted by a USD 4.2 billion 340B provision reversal.

• Free cash flow for 2026 projected at DKK 35–45 billion; CAPEX around DKK 55 billion.

• Effective tax rate expected at 21–23%.

• Margin discipline maintained through budget cuts in non-priority areas and focus on R&D and key growth drivers.